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Objective: The aim of the present review was to close the gap in the approach to pregnant women with
visceral leishmaniasis (kala-azar) by providing up-to-date information to obstetricians about physiopathology,
epidemiology, vertical transmission, drugs and treatment during pregnancy.
Background: Infection with Leishmania chagasi during pregnancy is rare and deserves special attention since
little information is available regarding the occurrence of visceral leishmaniasis during gestational period and the
real possibility of vertical transmission of this disease. Because speciﬁc areas in the world are endemic for the
disease and considering the continuous growth of the population, cases of pregnant women with visceral
leishmaniasis are becoming more frequent. Unfortunately, textbooks on infectious diseases do not include this
speciﬁc group of patients, and studies in the literature on aspects related to pregnancy and visceral leishmaniasis
are scarce.
Conclusions: Vertical transmission of leishmaniasis is possible and the institution of treatment is imperative in
cases of pregnant women with kala-azar. Amphotericin B is strongly recommended as the ﬁrst choice drug due
to its fewer maternal-fetal adverse effects.
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INTRODUCTION
According to Alencar et al.
1 visceral leishmania-
sis (VL) or kala-azar was ﬁrst described in
Greece in 1835, and subsequently in India in
1882. At that time, emphasis was placed on a
typical aspect of the disease found in India,
which did not usually manifest itself in Brazil,
i.e. the darkening of the skin. This characteristic
formed the basis of the ﬁrst denomination of
this disease, which was called ‘black fever’,
‘kala-jwar’ or ‘kalazar’ by Indians. Almost at the
same time, in 1903, Laveran and Mesnil
identiﬁed the parasite in material provided by
Leishman and Donovan. In honor of Leishman,
the disease associated with this parasite was
called leishmaniasis, which is the most widely
used terminology in western countries
1.
VL is a zoonosis of worldwide distribution and
mainly affects populations in developing coun-
tries. In addition to humans, VL is also found in
animals and its transmission, initially through wild
animals and so usually concentrated in small rural
localities, is increasingly observed in medium and
large urban centers in domiciliary and peridomi-
ciliary areas. The progressive expansion of VL
qualiﬁes this disease as a public health problem in
Brazil and in other South American countries due
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DOI: 10.1080/1064744042000210384to its endemic and sociodemographic character-
istics
2–4.
VL is a chronic systemic disease that is
characterized by persisting fever, weight loss,
asthenia, adynamia and anemia, among other
clinical manifestations. The disease is fatal when
untreated, with death generally occurring 1 to 2
years after the onset of clinical manifestations. The
etiological agent of this zoonosis is the protozoan
Leishmania chagasi, genus Leishmania, family Try-
panosomatidae. Its evolutive cycle is characterized
by two forms: the amastigote form (without
ﬂagella), an obligatory intracellular stage in
vertebrates; and the promastigote form (ﬂagel-
lated) found in the digestive tube of the insect
vector and in artiﬁcial culture media
1,2,5,6.
The reservoirs of L. chagasi are to be found in
the wild in foxes and marsupials. In urban areas,
the main source of infection is dogs, which might
develop clinical signs of the disease such as weight
loss, piloerection and loss of fur, nodules or
ulcerations in the ears, intestinal hemorrhage,
paralysis of the hind limbs, keratitis accompanied
by blindness, and cachexia, leading to death in
more severe cases. Since canids show intense
cutaneous parasitism, infection of the mosquito
vector is facilitated, and therefore these animals
become the most important link in the main-
tenance of the epidemiological chain
1–3.
In Brazil, the main vector responsible for the
transmission of VL is Lutzomyia longipalpis, a small
mosquito of sand-like color (sandﬂy) with large
hairy wings directed backwards and upwards, a
ﬂexed head, a gibbous body, and long maxillary
palpi. The mosquito inhabits the domiciliary and
peridomiciliary areas of human dwellings where it
feeds on the blood of dogs, humans, birds and
other mammals. Females have anthropophilic
habits, since they require blood for the develop-
ment of their eggs
1,2.
The mosquito becomes infected during a
blood meal through the ingestion of the
amastigote forms of Leishmania, found in the
cytoplasm of cells of the mononuclear phagocyte
system (macrophages) present in the dermis of
the infected host. In the midgut of the sandﬂy,
the amastigote forms transform into promasti-
gotes which adhere to the epithelium of the
digestive tube, initiating the process of multi-
plication (sexual) with migration to the anterior
intestine and differentiation into infectious pro-
mastigote forms, followed by invasion of the
insect’s pharynx. The females become infectious
3 to 4 days after feeding on contaminated
blood
1,2,5,6.
During a new blood meal, infectious promas-
tigote forms are deposited together with the saliva
of the sandﬂy inside the dermis of another host,
followed by the invasion of macrophages. These
infectious forms invade new macrophages where
they transform into amastigotes inside parasito-
phorous vacuoles and multiply until rupture of
the vacuole, which is followed by the invasion of
new macrophages. Hematogenic dissemination to
other tissues rich in cells of the mononuclear
phagocyte system, such as lymph nodes, liver,
spleen and bone marrow is observed
1,2,5,6.
The incidence of VL shows a sporadic or
endemoepidemic character in 18 (66.7%) states of
Brazil, with most Brazilian cases having been
reported in the north-eastern states. About 60% of
cases of the disease have been reported in children
younger than 4 years of age
7,8. On the other
hand, the involvement of adults has signiﬁcant
repercussions on the epidemiology of VL due to
the presence of asymptomatic forms, in addition
to clinically expressed forms
1–3.
Special attention should be paid to women
infected with L. chagasi during pregnancy, since
little information is available regarding the
proportion of infected pregnant women or their
geographical distribution. Kala-azar in pregnancy
is considered to be a rare occurrence in view of
the cases reported in the literature. However,
with the disease spreading among urban and
peri-urban areas in Brazil, where adults were
generally not previously exposed to Leishmania,
cases of pregnant women with VL have been
reported
9. Unfortunately, textbooks on infec-
tious diseases do not include this speciﬁc group
of patients, and studies in the literature on
aspects related to pregnancy and visceral leish-
maniasis are scarce
1–6,9. The aim of this review
was to close the gap in the approach to pregnant
women with VL by providing up-to-date
information to obstetricians about the manage-
ment of women affected by leishmaniasis during
pregnancy.
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LEISHMANIASIS
Although the insect vector represents the most
frequent and the most important route of
transmission of VL, other exceptional routes of
transmission have also been described, such as
direct dog-to-dog transmission, tick bites, blood
transfusion, sexual transmission, organ trans-
plants, and mother–child or congenital
transmission which is also called vertical trans-
mission
1,4.
Transplacental vertical transmission of leish-
maniasis has been studied experimentally in
pregnant dogs
10,11, however, Andrade et al.
12
did not conﬁrm this form of transmission in
these animals, suggesting that the experimental
vertical transmission reported by others might
have occurred during delivery. Despite the
consistency of the study by Andrade et al.
12,
the transplacental passage of various parasites
such as trypanosomatids and helminths has been
well established in different experimental in-
vestigations using models of pregnant
animals
13–17.
Until now, human studies detailing and
conﬁrming the vertical transmission of VL have
not been available. Evidence that the mother-to-
child transmission of VL is possible, although
rare, is known because of the human cases of
congenital VL that have been described world-
wide since 1926, emphasizing the strong
possibility of the vertical transmission of Leish-
mania chagasi
4,18–26.
Low and Cooke
18 reported the ﬁrst case of
kala-azar in pregnancy, which occurred in Africa,
with the child showing signs and symptoms of the
disease at birth. Banerji
19 reported the case of a
child born in England who manifested clinical
signs and symptoms of laboratory conﬁrmed VL
at 7 months of age. The child’s mother, whose
disease was acquired at 5 months gestation, was
returning to England from India where she had
lived for several years.
Nyakundi et al.
22 also reported on a 4-month-
old male infant born prematurely after 6 months
gestation with kala-azar. The child’s mother was
diagnosed as having VL during pregnancy. The
authors assumed that chronic infection with kala-
azar in the mother may have been the cause of the
reported previous fetal wastage.
Yadav et al.
23 described an 11-month-old male
infant admitted with symptoms that were later
conﬁrmed as VL. The baby’s mother had also
suffered from kala-azar while carrying this child.
As the baby and his mother did not leave New
Delhi, India, where the case was related, either
during or after the delivery and the vector found
in New Delhi was not competent to transmit
leishmaniasis, the infant could not have been
infected by the bite of a sandﬂy. It therefore seems
most likely that he was congenitally exposed to
kala-azar.
Eltoum et al.
24 reported two cases of congenital
kala-azar in the Sudan. The ﬁrst child, whose
mother had contracted kala-azar in southern
Sudan, was born in a Sudan area where no
transmissions of leishmaniasis were currently
occurring. At 7 months the child developed
characteristic symptoms of VL and died. The
autopsy showed leishmania parasites in all tissue,
including lungs, kidneys and thymus. In the
second case, parasites were found in the placenta
of a ﬁve-month-old fetus, conﬁrming the Leish-
mania’s transplacental passage during pregnancy.
Meinecke et al.
4 reported the case of a 16-
month-old German boy who was admitted to
hospital with signs and symptoms later con-
ﬁrmed as VL. Because the child had never left
Germany, nonvector transmission was suspected.
His mother had travelled to endemic Mediter-
ranean areas (Portugal, Malta and Corsica)
several times during her pregnancy. She had
never been symptomatic for kala-azar, but she
had a positive Montenegro skin test, indicating
a previous infection with Leishmania. In this
case it was also assumed that the asymptomatic
mother must have had a subclinical infection
with Leishmania that was reactivated by preg-
nancy, and had then congenitally transmitted it
to the child.
Table 1 data summarizes the cases of VL
reported thus far, indicating the real possibility of
mother-to-child transmission of this disease. In
almost all cases the mothers were symptomatic
and no treatment was established during preg-
nancy, although all the newborns received
speciﬁc treatment against the infection
4,18–26.
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OF VISCERAL LEISHMANIASIS
The clinical manifestations of VL during preg-
nancy do not differ from those observed in non-
pregnant patients, reﬂecting an imbalance be-
tween multiplication of the parasite in cells of the
mononuclear phagocyte system, the patient’s
immune response, and the underlying inﬂamma-
tory process. Many infected individuals show the
inapparent or oligosymptomatic form of the
disease, and the number of severe cases or cases
with clear clinical manifestations is relatively small.
Causes of death in patients with VL generally
include hemorrhage and associated infections due
to physical and immunological debilitation. Di-
dactically, VL can be classiﬁed into several
different forms in order to facilitate its study
1–3.
(A) Inapparent: patients with positive serology
or positive leishmanin test (Montenegro
skin test), or the detection of parasites in
tissue, without clinical manifestations.
(B) Oligosymptomatic: intermittent picture of
low or absent fever. Hepatomegaly is
present and splenomegaly, when detected,
is discrete. Adynamia and cachexia are
observed, but there are no reports of
hemorrhage.
(C) Acute: the onset can be abrupt or insidious.
In most cases fever is the ﬁrst symptom,
which can be high and continuous or
intermittent, followed by remission within
1 or 2 weeks. Hepatosplenomegaly, ad-
ynamia, weight loss and hemorrhage are
observed in addition to anemia accompa-
nied by hyperglobulinemia.
(D) Classic: a picture of prolonged evolution
which leads to nutritional impairment
accompanied by hair loss, ciliary growth
and brightness, and edema of the lower
limbs. Manifestations include fever, asthe-
nia, adynamia, anorexia, weight loss and
cachexia. Marked hepatosplenomegaly,
generalized micropolyadenopathy, and in-
tense pallor of the skin and mucosae as a
consequence of the severe anemia are
observed. Hemorrhagic phenomena such
as gingival bleeding, epistaxis, ecchymoses
and petechiae are frequent. Laboratory
exams reveal marked anemia, leukopenia,
thrombocytopenia (pancytopenia), hyper-
globulinemia, and hypoalbuminemia.
(E) Refractory: this is the evolutive form of
classic VL, which does not respond to
antimony treatment and is therefore con-
sidered to be clinically more severe.
The most common signs and symptoms according
to the presentation forms of visceral leishmaniasis
are listed on Table 2.
Table 1 Cases of congenital visceral leishmaniasis according to year of publication, country of origin, clinical manifestations,
maternal treatment and the treatment and evolution of the newborn
Mother Newborn
Case Reference Country Symptoms Treatment Treatment Evolution
1 Low and Cooke
18 England Yes No Yes Cure
2 Banerji
19 India Yes No Yes Cure
3 Blanc and Robert
20 France Yes No Yes Cure
4 Mittal et al.
21 India Yes No Yes Cure
5 Nyakundi et al.
22 Kenya Yes No Yes Cure
6 Yadav et al.
23 India Yes No Yes Cure
7–8 Eltoum et al.
24 Sudan Yes No Yes Death
9 Elamin and Omer
25 Sudan Yes No Yes Death
10 Sharma et al.
26 India No No Yes Cure
11 Meinecke et al.
4 Germany No No Yes Cure
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The diagnosis of VL follows successive steps that
are based on epidemiological, clinical and labora-
tory data. These aspects are presented on Table 3.
Epidemiological aspects
The origin of the patient and their visits to
endemic areas are extremely important for the
establishment of the diagnosis of VL. Patients
with characteristic symptoms who originate from
endemic areas and report previous contact with
individuals with the disease or the presence of sick
dogs in the vicinity, in addition to information
about the vector (trying to ﬁnd out if the patient
has been in contact with sandﬂy by its external
and speciﬁc characteristics questioning), should be
screened for possible VL infection
1–3,7.
Clinical aspects
The clinical forms observed during pregnancy
range from the inapparent form to the classical
form of the disease. In most cases, fever is the
ﬁrst symptom, accompanied by adynamia,
weight loss and hemorrhage, with the last
symptom often being confused with hemor-
rhagic conditions related to pregnancy itself.
The observation of hepatosplenomegaly can be
impaired because of the growth of the uterus.
Since the symptoms are nonspeciﬁc and are
easily confused with other clinical entities,
analysis of epidemiological and laboratory data
is essential. The clinical diagnosis becomes easier
as classical signs and symptoms of VL become
more exuberant, including manifestations such
as marked hepatosplenomegaly, signiﬁcant
weight loss, adynamia, intense anemia accom-
panied by an important decline in general
Table 3 Most common diagnosis aspects of visceral leishmaniasis during pregnancy
Diagnosis aspects of kala-azar
Epidemiological Clinical Laboratorial
Origin of patient Fever
Vector previous contact Adynamia Pancytopenia
Endemic areas Weight loss Anemia
Presence of sick dogs Hemorrhage Leukopenia
Report of VL contact Hepatosplenomegaly Lymphocytosis
Anemia Thrombocytopenia
Decline of general condition Inversion albumin/globulin ratio
Immunoﬂourescence 41: 40
ELISA IgG/IgM positive
Bone marrow, Lymph nodes and Spleen biopsy
(parasite direct observation)
Table 2 Kala-azar clinical presentations and the most common signs and symptoms
Most common signs and symptoms
Kala-azar clinical
presentation
Hyperglo-
bulinemia
Anemia Fever Hepato-
megaly
Spleno-
megaly
Adynamia Weight loss Hemorrhage
Oligosymptomatic 77 +/7 +/7 +/7 +/7 +/77
Acute + +/++ +/++ +/++ +/++ +/++ +/++ 7/+/++
Classic ++ ++/+++ ++/+++ +++ +++ ++/+++ ++/+++ ++/+++
(7): Absence (+): Present (++): Present and moderate (+++): Present and intense
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regarding the presence of the refractory form of
the disease during pregnancy
9,27–30. In these
situations, epidemiological and laboratory data
should be analyzed as a whole to conﬁrm the
diagnosis of infection.
Laboratory aspects
The laboratory diagnosis of VL is based on
nonspeciﬁc and speciﬁc subsidiary exams. Non-
speciﬁc subsidiary exams are important since they
provide guidance regarding both the diagnostic
suspicion and the patient’s process of cure, based
on alterations in blood cells and in protein
metabolism. Blood counts generally identify
pancytopenia, anemia, leukopenia, relative lym-
phocytosis and thrombocytopenia. The absence
of eosinophils is a typical ﬁnding, but when
associated with other diseases such as schistoso-
miasis or strongyloidiasis, the number of
eosinophils might be normal or elevated. Protein
determination shows a strong inversion of the
albumin/globulin ratio, with patterns as marked as
those observed in multiple myeloma
1–3,7.
Speciﬁc subsidiary exams include serological
and parasitological tests. Indirect immunoﬂuores-
cence (IF) permits the determination of IgG and
IgM class antibodies, with the result being
considered positive at dilutions equal to or higher
than 1: 40. Immunoenzymatic assays (ELISA) are
increasingly used and permit the determination of
IgG and IgM antibodies with sensitivity and
speciﬁcity rates that are higher than 97%
1.
Parasitological examination is performed on
material preferentially obtained from bone mar-
row, lymph nodes or spleen. Spleen biopsies
should be obtained in the hospital under surgical
conditions. In pregnant patients, sternal bone
marrow biopsies are preferred over lymph node
aspirates and spleen biopsy.
Differential diagnosis
Many clinical entities can be confused with VL,
among them a prolonged enterobacterial infec-
tion (a combination of schistosomiasis with
salmonella or another enterobacteria) whose
clinical manifestations perfectly overlap with the
signs and symptoms of VL, malaria, brucellosis,
typhoid fever, acute Chagas’ disease, hepatosple-
nic schistosomiasis, lymphoma, multiple
myeloma, sickle cell anemia, and leukemias
1–3,7.
TREATMENT
VL requires hospitalization, which should be
maintained throughout treatment. Pentavalent
antimonial compounds (Sb
+5) are considered to
be the drugs of choice in these cases. In an
attempt to standardize the therapeutic scheme, the
World Health Organization recommends that the
antimonial dose be calculated in mg Sb
+5/kg/
day. The product marketed in Brazil is N-
methylglucamine antimoniate (Glucantime
1),
which is available in the form of 5 ml ﬂasks
containing 425 mg/Sb
+5, corresponding to
85 mg Sb
+5/ml. The recommended dose is
20 mg Sb
+5/kg/day, administered by the par-
enteral route (intravenous or intramuscular), with
a maximum of three ampullae/day (1275 mg
Sb
+5/day) for a minimum of 20 and a maximum
of 40 consecutive days
1,2,31.
Antimony is contraindicated in patients with
renal or hepatic failure, cardiac arrhythmias and
Chagas’ disease. Clinical follow-up includes
complementary exams (blood count, determina-
tion of urea, creatinine, glutamic-oxaloacetic
transaminase (GOT), and glutamic-pyruvic trans-
aminase (GPT)) which are recommended in order
to detect possible time-dependent manifestations
of intoxication. The most common side effects
are arthralgia, myalgia, pruritus, adynamia, anor-
exia, nausea, vomiting, gastric fullness, heartburn,
abdominal pain, fever, weakness, headache,
dizziness, palpitation, insomnia, irritability, pyro-
genic shock, and edema. Herpes zoster, acute
renal failure and pancreatitis are severe complica-
tions observed with the use of antimonial drugs.
The most feared adverse effect of pentavalent
antimonial drugs is cardiotoxicity, which should
be monitored on periodic electrocardiograms
(ECG) for the detection of changes in the QT
segment. Nonspeciﬁc alterations in ventricular
repolarization are frequent and, as long as the
QT interval is not prolonged, medication should
not be discontinued. The ﬁrst control ECG
should be obtained 5 days after the beginning of
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dicated in cases of cardiotoxicity, renal failure
and pancreatitis
1,5,6,31.
In cases where leishmania is resistant to
antimony, the second choice drug is amphotericin
B. The total daily dose ranges from 1 to 1.5 mg/
kg (maximum of 50 mg/day); however, treat-
ment should be started with 0.5 mg/kg/day until
the total daily dose of 1 to 1.5 mg/kg is reached.
Each milligram of drug is reconstituted in 10 mg
distilled water and 1 mg of the solution is diluted
in 10 ml 5% glucose serum at the time of
administration. Due to the risk of precipitation,
amphotericin B must not be administered to-
gether with other drugs or solutions containing
electrolytes, and the drug should be protected
from light. Amphotericin B is infused intrave-
nously at a slow rate (over a period of 4 to
6 hours, at a maximum of 50 mg/dose/day) on
consecutive days for a period of 14 days. In view
of its toxicity, amphotericin B should be
administered under medical supervision and the
patients should be under hospitalization
1,5,6,31.
In the case of patients that are refractory to
treatment with amphotericin B, pentamidine is
indicated at the dose of 4 mg/kg, three times a
week for 5 to 25 weeks, depending on the
response. The drug is administered by the
parenteral route (intramuscular or intravenous)
and might cause local pain, nausea, vomiting,
abdominal pain, hypotension, hypoglycemia, and
diabetes mellitus
31.
The treatment success rates are high, ranging
from 95–100% depending on the drug used.
Drug resistance, when it occurs, is due to the
patient’s immunity factors, and has no relation to
parasite factors at all
1,9.
TREATMENT OF PREGNANT WOMEN
The occurrence of VL during pregnancy is rare,
both in Brazil and worldwide, considering that
90% of cases of the disease are observed in
children younger than 10 years of age. However,
with the spreading of the disease to peri-urban
areas, where adults have not generally been
previously exposed to L. chagasi, cases of VL in
pregnant women have been reported
1,2,9. Con-
genital and post-natal transmission of leishmaniasis
has already been documented. Therefore, treat-
ment of pregnant women has a double indication:
to treat the patient and to prevent vertical
transmission
27–30,32.
Important considerations in this respect refer to
the drugs currently available for the treatment of
VL in pregnant women, their possible teratogenic
effects and toxicity to the fetus. Despite the fact
that pentavalent antimonial organic compounds
have been used in clinical practice for more than
50 years, information on their safety during
pregnancy is still scant. Some authors indicate
that it should be avoided once teratogenity and
security of these compounds during pregnancy
are not well established
33,34, whereas others say
that mutagenic, carcinogenic and teratogenic risks
of antimony compounds are not very important,
and so the usage during pregnancy may not cause
important maternal-fetal injury
35.
Paumgartten and Chahoud
34 described that the
experimental repeated administration of meglu-
mine antimoniate was embryolethal and
teratogenic in rats, but no maternal toxicity and
no reduction of fetal weight were noted in the
treated groups. It was also reported that pentava-
lent antimony compounds cross the placental
barrier and may impregnate fetal nervous tissue,
leading to severe syndromes of mental retarda-
tion
36.
Another clinical report has shown no adverse
fetal effects of pentavalent antimony administered
during the second trimester of gestation at the
dose of 850 mg Sb
+5/day, with the child
delivered at term showing no alterations and
being free of the disease
29. However, this report is
the only one available thus far using antimony
compounds during pregnancy, and cases of
pregnant women being treated with antileishma-
nial drugs are rare (Table 4).
Amphotericin B is the second drug of choice
for the treatment of VL in non-pregnant patients;
however, due to its high nephro- and cardiotoxi-
city the drug should be administered under strict
care. Since amphotericin B has been recognized as
a drug with a leishmanicidal action but high toxic
potential, therapeutic schemes have been mod-
iﬁed over the years, a fact that led to progressive
reduction and control of its toxicity and side
effects
37,38,39. Amphotericin B crosses the pla-
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fetus do not exceed one third of those observed in
maternal plasma
31. Based on the high cure rates of
kala-azar (95–100%)
1,9,39, the use of amphoter-
ecin B has been extended and its safe use in
pregnant women without repercussions on the
fetus has been reported
9,27,28,30 (Table 4).
Various other drugs have been employed in the
treatment of VL, with aminosidine being another
option for treatment during pregnancy. The
precautions and restrictions are the same that
apply to the use of aminoglycosides during
pregnancy. The recommended daily dose is
12–16 mg/kg, administered intramuscularly for
15–20 days. Another series lasting 10–15 days
might be repeated one month after treatment if
amastigote forms persist in the bone marrow. The
response to aminosidine is generally slower than
that observed during treatment with the ﬁrst and
second choice drugs previously mentioned. The
monitoring of renal function is obligatory.
However, no reports exist regarding the use of
aminosidine during pregnancy
1,9,27–30.
During the lactation period, if the mother is
being treated with Sb
+5 compounds, the
newborn should be breast-fed 5 to 6 hours after
drug administration to the mother, when
antimony levels in the milk become neglible.
If amphotericin B is being used, no remarkable
recommendations concerning lactation are
needed
31.
CONCLUSIONS
A present review of the literature shows that the
occurrence of VL during pregnancy involves a
real risk of vertical transmission
4,18–26 as can be
seen in Table 1. The reported cases of congenital
leishmaniasis mainly involved untreated sympto-
matic women. Cure of newborns submitted to
post-natal treatment was observed in 73% of
cases
4,18–23,26 while death occurred in 27% of
cases
24,25.
No vertical transmission was observed in the
nine cases reported in the literature who received
anti-leishmanial drugs during pregnancy
9,27–30.
This is evidence that the prenatal treatment of
pregnant infected women results in no-newborn
infection, but additional trials are needed to state
whether treatment actually avoids the parasite
infection to the fetus and how effective it really is
during pregnancy (Table 4).
In the cases reported in Table 4, the drugs were
administered after the second trimester at variable
doses and the fact that these cases represented
isolated reports using different and uncontrolled
strategies did not permit a deﬁnition of the best
therapeutic option
9,27–30. Only one group stu-
died a series of ﬁve patients using the same
amphotericin B regimen administered to pregnant
women and observed no mother-to-child trans-
mission of the parasite
27.
Caldas et al.
9 reported on a 17-year-old
Brazilian pregnant patient admitted with VL
during the ﬁrst trimester of gestation. This patient
was treated with 1 mg/kg of amphotericin B for
14 days. The patient was then followed-up after
treatment at 3-month intervals for 12 months, and
demonstrating no signs or symptoms of VL. She
had a vaginal delivery at 9 months gestation and
gave birth to a healthy boy weighing 2485g, with
no abnormalities upon physical examination. No
vertical transmission was observed, and the child
was followed-up clinically and serologically for 10
months without showing any signs or symptoms
of the disease, even though he was living in an
Table 4 Reports available in the literature regarding treatment of symptomatic pregnant women with visceral
leishmaniasis (VL)
No. of cases Reference Country Drug used Daily dose Period Congenital VL
5 Thakur et al.
27 India Amphotericin B 1–20 mg/kg 2
nd–3
rd trimester No
1 Grandoni et al.
28 Italy Amphotericin B 18 mg/kg 3
rd trimester No
1 Utili et al.
29 Italy Antimony 850 mg Sb
+5 2
nd trimester No
1 Kumar et al.
30 India Amphotericin B 1 mg/kg 3
rd trimester No
1 Caldas et al.
9 Brazil Amphotericin B 1mg/kg 1
st trimester No
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the placenta did not reveal any parasites, thus
suggesting the absence of Leishmania transmission
from the mother to the infant.
Until new studies become available, ampho-
tericin B seems to be the ﬁrst choice regimen
while treating pregnant patients with kala-
azar
9,27,28,30, leading to high cure rates associated
with a reduced total dose, according to informa-
tion extracted from the cases listed on Table 4.
Based on the above considerations, it is clear
that more consistent studies are necessary to
deﬁne the best and safest drug for women
infected with L. chagasi during pregnancy, in
order to prevent vertical transmission. During
pregnancy, a shift from cell-mediated to
humoral immunity has been described in mice
as well as in humans
40. Therefore, females may
have a higher susceptibility to leishmaniasis
during pregnancy, as has been shown in mice
41.
This may also suggest that pregnancy can trigger
the (re)activaction of leishmaniasis
4. According
to Kumar et al.
30 and Caldas et al.
9, the
institution of treatment is imperative in cases
of pregnant women with leishmaniasis, with
amphotericin B being recommended as the ﬁrst
choice drug because of its fewer maternal-fetal
adverse effects.
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